Transgenomic to Raise $22M in Private Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic announced today it has entered into definitive agreements to raise about $22 million in a private placement.

The deal is with institutional and other accredited investors and as part of it, the Omaha, Neb.-based firm will issue an aggregate of 19 million shares of its stock at $1 per share and five-year warrants to purchase up to an aggregate of 9.5 million shares of Transgenomic stock at an exercise price of $1.25 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.